Japan Drug Makers Compete With Strategies In Emerging Markets
This article was originally published in PharmAsia News
Executive SummaryMajor Japanese drug makers are facing competition among themselves to see which can come up with best strategies for excelling in emerging markets, analysts say
You may also be interested in...
Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.
Swissmedic will scale back its review procedure for certain anti-infectives if the indications for which approval is being sought are identical to those approved in the EU or the US.
Neon listed on the NASDAQ at $16 per share 18 months ago. It has now been picked up by the ambitious German biotech for just $2.18 per share, having recently ended its cancer vaccine programs and laid off a quarter of its workforce.